Genetic alterations at 13q14 may correlate with differences in the biological behavior of prostate cancer between japanese and caucasian men

Urologia Internationalis

Volumn 84, Issue 4, 2010, Pages 461-466

  Misumi, Taku ^a   Yamamoto, Yoshiaki ^a   Murakami, Tomoyuki ^b   Kawai, Yoshihisa ^a   Ito, Hideaki ^a   Eguchi, Satoshi ^a   Yano, Seiji ^a   Nagao, Kazuhiro ^a   Hara, Takahiko ^a   Sakano, Shigeru ^a   Naito, Katsusuke ^c   Sasaki, Kohsuke ^a   Fuellhase, Claudius ^d   Arenas, Luis ^d   Fichtner, Jan ^d   Matsuyama, Hideyasu ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Kanmon Medical Center   (France)

^c Mine Municipal Hospital   (Japan)

^d Department of Urology   (Germany)

Author keywords

13q14; Allelic imbalance; Genetic alteration; Loss of heterozygosity; Prostate cancer

Indexed keywords

AGED; ALLELIC IMBALANCE; ARTICLE; BENIGN TUMOR; BIOLOGICAL TRAIT; CANCER STAGING; CAUCASIAN; CHROMOSOME 13Q; CHROMOSOME LOSS; CONTROLLED STUDY; DISEASE ACTIVITY; ETHNIC DIFFERENCE; GENE FREQUENCY; GENETIC ASSOCIATION; GERMANY; GLEASON SCORE; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; JAPANESE; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE MARKER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; ADENOCARCINOMA; ASIAN CONTINENTAL ANCESTRY GROUP; CHI SQUARE DISTRIBUTION; CHROMOSOME 13; COMPARATIVE STUDY; EPIDEMIOLOGY; ETHNOLOGY; GENETICS; GENOTYPE; JAPAN; MIDDLE AGED; PATHOLOGY; PHENOTYPE; PROGNOSIS; PROSTATE TUMOR;

MICROSATELLITE DNA;

ADENOCARCINOMA; AGED; ALLELIC IMBALANCE; ASIAN CONTINENTAL ANCESTRY GROUP; CHI-SQUARE DISTRIBUTION; CHROMOSOMES, HUMAN, PAIR 13; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENOTYPE; GERMANY; HUMANS; JAPAN; LOSS OF HETEROZYGOSITY; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; NEOPLASM STAGING; PHENOTYPE; POLYMERASE CHAIN REACTION; PROGNOSIS; PROSTATIC NEOPLASMS;

EID: 77953211831     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000296291     Document Type: Article

References (31)

1. Pienta KJ, Esper PS: Risk factors for prostate cancer. Ann Intern Med 1993; 118: 793-803.
2. Harada M, Nemoto R, Uchida K, Akaza H, Koiso K, Mostofi FK: Histopathological comparison of prostatic adenocarcinoma in Japan and the United States. Nippon Hinyokika Gakkai Zasshi 1993; 84: 1110-1118. (Pubitemid 23240451)
3. Naito S, Kuroiwa K, Kinukawa N, et al: Validation of Partin tables and development of a preoperative nomogram for Japanese patients with clinically localized prostate cancer using 2005 International Society of Urological Pathology consensus on Gleason grading: data from the Clinicopathological Research Group for Localized Prostate Cancer. J Urol 2008; 180: 904-909; discussion 909-910.
4. Shimizu H, Ross RK, Bernstein L, Yatani R, Henderson BE, Mack TM: Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer 1991; 63: 963-966.
5. Cook LS, Goldoft M, Schwartz SM, Weiss NS: Incidence of adenocarcinoma of the prostate in Asian immigrants to the United States and their descendants. J Urol 1999; 161: 152-155.
6. Watanabe M, Fukutome K, Shiraishi T, et al: Differences in the p53 gene mutational spectra of prostate cancers between Japan and Western countries. Carcinogenesis 1997; 18: 1355-1358.
7. Matsuyama H, Pan Y, Oba K, et al: Deletions on chromosome 8p22 may predict disease progression as well as pathological staging in prostate cancer. Clin Cancer Res 2001; 7: 3139-3143.
8. Visakorpi T, Kallioniemi AH, Syvanen AC, et al: Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res 1995; 55: 342-347.
9. Cher ML, Bova GS, Moore DH, et al: Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res 1996; 56: 3091-3102.
10. Matsuda K, Matsuyama H, Hara T, et al: DNA sequence copy number aberrations in prostate cancers: a comparison of comparative genomic hybridization data between Japan and European countries. Cancer Genet Cytogenet 2004; 152: 119-123.
11. Kasahara K, Taguchi T, Yamasaki I, Kamada M, Shuin T: Genetic changes in localized prostate cancer of Japanese patients shown by comparative genomic hybridization. Cancer Genet Cytogenet 2005; 159: 84-88.
12. Fukasawa S, Kino M, Kobayashi M, et al: Genetic changes in pT2 and pT3 prostate cancer detected by comparative genomic hybridization. Prostate Cancer Prostatic Dis 2008; 11: 303-310.
13. Kobayashi M, Ishida H, Shindo T, et al: Molecular analysis of multifocal prostate cancer by comparative genomic hybridization. Prostate 2008; 68: 1715-1724.
14. Cooney KA, Wetzel JC, Merajver SD, Macoska JA, Singleton TP, Wojno KJ: Distinct regions of allelic loss on 13q in prostate cancer. Cancer Res 1996; 56: 1142-1145.
15. Dong JT, Boyd JC, Frierson HF Jr: Loss of heterozygosity at 13q14 and 13q21 in high grade, high stage prostate cancer. Prostate 2001; 49: 166-171.
16. Hyytinen ER, Frierson HF Jr, Boyd JC, Chung LW, Dong JT: Three distinct regions of allelic loss at 13q14, 13q21-22, and 13q33 in prostate cancer. Genes Chromosomes Cancer 1999; 25: 108-114.
17. Melamed J, Einhorn JM, Ittmann MM: Allelic loss on chromosome 13q in human prostate carcinoma. Clin Cancer Res 1997; 3: 1867-1872.
18. Ueda T, Emi M, Suzuki H, et al: Identification of a I-cM region of common deletion on 13q14 associated with human prostate cancer. Genes Chromosomes Cancer 1999; 24: 183-190.
19. Sobin L, Wittekind C (eds): TNM Classification of Malignant Tumours, ed 5. New York, Wiley, 1997.
20. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL: The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005; 29: 1228-1242.
21. Noutomi Y, Oga A, Uchida K, et al: Comparative genomic hybridization reveals genetic progression of oral squamous cell carcinoma from dysplasia via two different tumourigenic pathways. J Pathol 2006; 210: 67-74.
22. Fukunaga K, Wada T, Matsumoto H, Yoshihiro S, Matsuyama H, Naito K: Renal cell carcinoma: allelic loss at chromosome 9 using the fluorescent multiplex-polymerase chain reaction technique. Hum Pathol 2002; 33: 910-914.
23. Korenaga Y, Matsuyama H, Hirata H, et al: Smoking may cause genetic alterations at 5q22.2 approximately q23.1 in clear-cell renal cell carcinoma. Cancer Genet Cytogenet 2005; 163: 7-11.
24. Canzian F, Salovaara R, Hemminki A, et al: Semiautomated assessment of loss of heterozygosity and replication error in tumors. Cancer Res 1996; 56: 3331-3337.
25. Fukagai T, Namiki TS, Carlile RG, Yoshida H, Namiki M: Comparison of the clinical outcome after hormonal therapy for prostate cancer between Japanese and Caucasian men. BJU Int 2006; 97: 1190-1193.
26. Zeigler-Johnson CM, Rennert H, Mittal RD, et al: Evaluation of prostate cancer characteristics in four populations worldwide. Can J Urol 2008; 15: 4056-4064.
27. Sossey-Alaoui K, Kitamura E, Head K, Cowell JK: Characterization of FAM10A4, a member of the ST13 tumor suppressor gene family that maps to the 13q14.3 region associated with B-Cell leukemia, multiple myeloma, and prostate cancer. Genomics 2002; 80: 5-7.
28. Dong XY, Chen C, Sun X, et al: FOXO1A is a candidate for the 13q14 tumor suppressor gene inhibiting androgen receptor signaling in prostate cancer. Cancer Res 2006; 66: 6998-7006.
29. Dong JT, Chen C, Stultz BG, Isaacs JT, Frierson HF Jr: Deletion at 13q21 is associated with aggressive prostate cancers. Cancer Res 2000; 60: 3880-3883.
30. Jeronimo C, Henrique R, Campos PF, et al: Endothelin B receptor gene hypermethylation in prostate adenocarcinoma. J Clin Pathol 2003; 56: 52-55.
31. Chen C, Bhalala HV, Vessella RL, Dong JT: KLF5 is frequently deleted and down-regulated but rarely mutated in prostate cancer. Prostate 2003; 55: 81-88.